PCRX - Pacira BioSciences, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $0.85
|
Rev Est: $201.9M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$27.00
DETAILS
HIGH:
$27.00
LOW:
$27.00
MEDIAN:
$27.00
CONSENSUS:
$27.00
UPSIDE:
15.34%
Market Cap:
1.01B
Volume:
543,176
Avg Volume:
870,786
52 Week Range:
18.8-27.64
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Beta:
0.23
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
788
IPO Date:
2011-02-03
EPS (TTM):
-2.15
P/E Ratio:
-8.75
Revenue (TTM):
700.97M
Total Assets:
1.55B
Total Debt:
638.85M
Cash & Equiv:
276.77M
Rev Growth (5Y):
10.7%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
24.2%
ROCE:
-4.0%
Debt/Equity:
0.82
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $0.70 | $0.65 | +7.7% | $179.5M | $201.9M | -11.1% |
| 2025-08-05 | $0.74 | $0.72 | +2.8% | $181.1M | $182.4M | -0.7% |
| 2025-05-08 | $0.62 | $0.57 | +8.8% | $168.9M | $187.5M | -9.9% |
| 2025-02-27 | $0.91 | $0.78 | +16.7% | $187.3M | $185.4M | +1.0% |
| 2024-11-06 | $0.79 | $0.72 | +9.7% | $168.6M | $179.5M | -6.1% |
| 2024-07-30 | $0.89 | $0.73 | +21.9% | $178.0M | $172.5M | +3.2% |
| 2024-05-07 | $0.62 | $0.64 | -3.1% | $167.1M | $165.3M | +1.1% |
| 2024-02-29 | $0.89 | $0.89 | 0.0% | $181.2M | $181.7M | -0.2% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 700.97M | 674.98M | 666.82M | 541.53M | 429.65M | 421.03M | 337.28M | 286.63M | 276.37M | 249.00M | 197.67M | 85.55M |
| Net Income | (99.56M) | 41.95M | 15.91M | 41.98M | 145.52M | (11.02M) | (471,000) | (42.61M) | (37.95M) | 1.86M | (13.72M) | (63.91M) |
| EPS | -2.15 | 0.91 | 0.35 | 0.95 | 3.41 | -0.27 | -0.01 | -1.07 | -1.02 | 0.05 | -0.39 | -1.93 |
| Total Assets | 1.55B | 1.57B | 1.68B | 2.08B | 1.27B | 831.07M | 689.35M | 628.37M | 391.47M | 389.62M | 326.07M | 169.82M |
| Total Debt | 638.85M | 586.04M | 763.39M | 1.13B | 541.13M | 351.92M | 290.93M | 276.50M | 108.74M | 105.93M | 103.10M | 98.96M |
| Cash & Equivalents | 276.77M | 153.30M | 104.14M | 585.58M | 99.96M | 78.23M | 132.53M | 54.13M | 35.94M | 158.97M | 158.17M | 12.52M |
| Operating Cash Flow | 189.39M | 154.65M | 145.27M | 125.72M | 77.03M | 70.52M | 48.87M | 17.79M | 33.45M | 29.00M | 25.47M | (43.22M) |
| Free Cash Flow | 178.75M | 139.49M | 115.20M | 79.85M | 39.23M | 60.36M | 34.36M | (1.48M) | 8.74M | (12.27M) | 3.58M | (56.01M) |
| FCF per Share | 3.87 | 3.02 | 2.53 | 1.80 | 0.92 | 1.45 | 0.84 | -0.04 | 0.24 | -0.34 | 0.10 | -1.69 |
| Book Value | 778.35M | 870.13M | 775.01M | 730.41M | 619.69M | 354.94M | 321.23M | 279.48M | 218.98M | 218.39M | 171.15M | 41.25M |
| Cash & ST Investments | 484.62M | 278.58M | 288.65M | 656.41M | 521.66M | 291.95M | 383.45M | 311.35M | 172.60M | 158.97M | 158.17M | 72.15M |
| ROC Equity | -0.13 | 0.05 | 0.02 | 0.06 | 0.23 | -0.03 | -0.00 | -0.15 | -0.17 | 0.01 | -0.08 | -1.55 |